RecruitingNot Applicable

A Randomized Controlled Study of the NEURESCUE Device as an Adjunct to Advanced Cardiac Life Support

Germany84 participantsStarted 2025-07-07

Plain-language summary

The NEURESCUE device is the first intelligent balloon catheter for aortic balloon occlusion (ABO), an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment. The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body. The purpose of this study is to compare the clinical safety and performance of Advanced Cardiovascular Life Support (ACLS) versus ACLS in combination with Aortic Balloon Occlusion (ABO) using the NEURESCUE device in subjects with cardiac arrest.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 and ≤80 years * Witnessed arrest * CPR initiated within 7 min of arrest * CPR time less than 40 min at enrollment * Non-shockable rhythm Exclusion Criteria: * Traumatic cardiac arrest * Known pregnancy * Known terminal disease * Known do-not-attempt-CPR order * Known opposition to study participation

What they're measuring

Resuscitation

Timeframe: Measured from 10 minutes after randomization to 70 minutes after randomization

Trial details

NCT IDNCT06793033

Sponsorneurescue

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-01

Contact for this trial

Michael Preusch, M.D.

+49 151 40044669‬ Michael.Preusch@med.uni-heidelberg.de

View on ClinicalTrials.gov More Cardiac Arrest (CA) trials